Silvercrest Asset Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Silvercrest Asset Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,062	Closed	-$17K	–	901
2020 Q4	$17K	Hold	25,062	–	–	﹤0.01%	808
2020 Q3	$56K	Sell	25,062 -1,575	-6%	-$4.5K	﹤0.01%	744
2020 Q2	$95K	Hold	26,637	–	–	﹤0.01%	717
2020 Q1	$101K	Hold	26,637	–	–	﹤0.01%	673
2019 Q4	$80K	Buy	+26,637	New	+$69.3K	﹤0.01%	740

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Silvercrest Asset Management's BMY.RT Position: Q1 2021 in Review

Silvercrest Asset Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 25,062 shares — an estimated $17K sold.

Silvercrest Asset Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $101K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Silvercrest Asset Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Silvercrest Asset Management sold 25,062 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $17K.
Silvercrest Asset Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Silvercrest Asset Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $101K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Silvercrest Asset Management's 13F filing for Q1 2021, filed 17 May 2021.